Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis
- PMID:14532767
- DOI: 10.1097/01.ju.0000092764.81308.6a
Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis
Abstract
Purpose: Renal cell carcinoma (RCC) can present with a wide range of signs and symptoms. To our knowledge we report the first study to describe the frequency of paraneoplastic findings in a modern RCC series and assess the prognostic significance of each finding.
Materials and methods: Using the kidney cancer database at our institution 1,046 patients undergoing nephrectomy for RCC between 1989 and 2001 were assessed. The prognostic significance of symptoms present at diagnosis and findings on preoperative laboratory evaluation were examined in a univariate analysis as well as on multivariate analysis controlling for TNM stage, Fuhrman grade and Eastern Cooperative Oncology Group performance status (ECOG-PS).
Results: Mean followup to date of death or last contact for all patients was 40.3 months. Median time to death was 19.3 months. Most paraneoplastic signs and symptoms correlated with poor survival, although on multivariate analysis hypoalbuminemia, weight loss, anorexia and malaise predicted shorter survival. The frequency of each of these findings was 19.9%, 22.9%, 10.6% and 19.1%, respectively. Cachexia, defined as the presence of at least 1 of these findings, was noted in 35.3% of patients. Cachexia did not predict a higher recurrence rate in patients with localized disease and only malaise correlated with a decreased likelihood of responding to immunotherapy.
Conclusions: Cachexia, defined as hypoalbuminemia, weight loss, anorexia or malaise, predicts worse survival after controlling for well established indicators of prognosis (TNM stage, Fuhrman grade and ECOG-PS). Consideration should be given to expanding the ECOG-PS to include measures for cachexia when applied to patients with RCC.
Similar articles
- Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma.Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS.Kim HL, et al.J Urol. 2004 May;171(5):1810-3. doi: 10.1097/01.ju.0000121440.82581.d3.J Urol. 2004.PMID:15076282
- Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.Wagner B, Patard JJ, Méjean A, Bensalah K, Verhoest G, Zigeuner R, Ficarra V, Tostain J, Mulders P, Chautard D, Descotes JL, de la Taille A, Salomon L, Prayer-Galetti T, Cindolo L, Valéri A, Meyer N, Jacqmin D, Lang H.Wagner B, et al.Eur Urol. 2009 Feb;55(2):452-9. doi: 10.1016/j.eururo.2008.07.053. Epub 2008 Aug 5.Eur Urol. 2009.PMID:18692951
- Influence of tumour-associated symptoms on the prognosis of patients with renal cell carcinoma.Kawaciuk I, Hyrsl L, Dusek P, Jarolim L, Schmidt M, Kaliska V, Chocholaty M, Vesely S.Kawaciuk I, et al.Scand J Urol Nephrol. 2008;42(5):406-11. doi: 10.1080/00365590802022151.Scand J Urol Nephrol. 2008.PMID:18932106
- Paraneoplastic manifestations of renal cell carcinoma.Gold PJ, Fefer A, Thompson JA.Gold PJ, et al.Semin Urol Oncol. 1996 Nov;14(4):216-22.Semin Urol Oncol. 1996.PMID:8946620Review.
- [Paraneoplastic nephropathy associated with adult renal carcinoma (immunologic and clinicopathologic study)].Kiss B, Magyarlaki T, Buzogány I, Fazekas A, Sükösd F, Nagy J.Kiss B, et al.Orv Hetil. 1999 Jan 10;140(2):75-80.Orv Hetil. 1999.PMID:9949663Review.Hungarian.
Cited by
- Molecular signature of renal cell carcinoma by means of a multiplatform metabolomics analysis.Kordalewska M, Wawrzyniak R, Jacyna J, Godzień J, López Gonzálves Á, Raczak-Gutknecht J, Markuszewski M, Gutknecht P, Matuszewski M, Siebert J, Barbas C, Markuszewski MJ.Kordalewska M, et al.Biochem Biophys Rep. 2022 Aug 4;31:101318. doi: 10.1016/j.bbrep.2022.101318. eCollection 2022 Sep.Biochem Biophys Rep. 2022.PMID:35967759Free PMC article.
- Prognostic factors in renal cell carcinoma.Volpe A, Patard JJ.Volpe A, et al.World J Urol. 2010 Jun;28(3):319-27. doi: 10.1007/s00345-010-0540-8. Epub 2010 Apr 3.World J Urol. 2010.PMID:20364259Review.
- Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis.Hu X, Wang Y, Yang WX, Dou WC, Shao YX, Li X.Hu X, et al.Cancer Manag Res. 2019 Jul 4;11:6163-6173. doi: 10.2147/CMAR.S208839. eCollection 2019.Cancer Manag Res. 2019.PMID:31308752Free PMC article.
- [Paraneoplastic syndrome in renal cell carcinoma].Bedke J, Buse S, Kurosch M, Haferkamp A, Jäger D, Hohenfellner M.Bedke J, et al.Urologe A. 2007 Jan;46(1):45-8. doi: 10.1007/s00120-006-1269-2.Urologe A. 2007.PMID:17186189Review.German.
- Staging of renal cell carcinoma: Current concepts.Lam JS, Klatte T, Breda A.Lam JS, et al.Indian J Urol. 2009 Oct-Dec;25(4):446-54. doi: 10.4103/0970-1591.57906.Indian J Urol. 2009.PMID:19955666Free PMC article.
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Medical